CTF: Neurofibromatosis type 1 (NF1) Gene Therapy Initiative RFA - LOI

Sponsor Deadline: 

Jul 22, 2022

Letter of Intent Deadline: 

Jun 15, 2022


Children's Tumor Foundation

UI Contact: 

ProposalCentral link https://proposalcentral.com/grantopportunities.asp?GMID=191#

The objective of this Request for Applications (RFA) is to support studies to investigate the feasibility of gene therapy strategies to treat NF1 plexiform neurofibromas and/or MPNSTs. Investigators should describe and provide rationale for the target(s), therapeutic molecules, method(s) of therapy delivery, outcome measures to evaluate success and off-target effects, feasibility, and applicability among NF1 patients. All approaches will be considered. Innovation using newest approaches to optimize success while minimizing risk will be viewed particularly favorably. Investigators should outline how their approach, if successful, would lead to clinical application. Investigative groups should not only contain expertise in the strategy and tumor therapeutics, but familiarity with NF1. CTF will be happy to guide teams to NF1 expert consultants/collaborators as needed.

CTF intends to allot up to $1.5M to fund approximately three applications. Funding of applications is contingent upon the number of applications received, the quality and merit of the applications as evaluated by our review panel, and the requirements of this RFA